JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
JB Chemicals & Pharmaceuticals Ltd has filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, covering the period April 1, 2025 to March 31, 2026. The company reported turnover of Rs 3,88,988.84 lakhs with 79% from manufacturing and 21% from trading. Key products include Oral Solids (58%), Injectables (18%), Liquids (8%), and Lozenges (6%). The company operates 8 manufacturing plants in India and serves 28 states domestically plus 40+ countries internationally, with exports contributing 35% of total turnover. Notable ESG achievements include 43% renewable energy usage, zero fatalities, all plants achieving Zero Liquid Discharge, and Scope 1 emissions reduced by >7%. The company has committed to 100% renewable energy and carbon neutrality by FY 2032-33. The report was assured by DNV Business Assurance India Private Limited. Total permanent employees stand at 5,324 with 278 permanent workers. Women represent 12.5% on the Board of Directors.
The BRSR filing demonstrates JB Pharma's commitment to ESG transparency with measurable environmental targets and governance disclosures. The low female representation on the board (12.5%) may attract regulatory scrutiny under SEBI's diversity requirements. Strong safety performance (zero fatalities) and renewable energy progress support the company's sustainability narrative for investors.